KAM
VIRX

Kazazian Asset Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Kazazian Asset Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,000
Closed -$70K – 90
2018
Q3 		$70K Buy
+1,000
New +$75.9K 0.07% 89

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Kazazian Asset Management's VIRX Position: Q4 2018 in Review

Kazazian Asset Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2018, closing a stake of 1,000 shares — an estimated $70K sold.

Kazazian Asset Management first reported a position in VIRX in Q3 2018 and held it in 1 quarter. The position peaked at $70K in Q3 2018. 40 funds tracked by Wall St. Rank hold VIRX as of Q4 2018.

  • Kazazian Asset Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Kazazian Asset Management sold 1,000 Viracta Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $70K.
  • Kazazian Asset Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Kazazian Asset Management's Viracta Therapeutics, Inc. Common Stock position peaked at $70K in Q3 2018.
  • 40 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Kazazian Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.